FOR IMMEDIATE RELEASE
GAINESVILLE, FL. Automated Imaging Diagnostics (AID), a wholly-owned subsidiary of neuropacs Corp., a pioneering force in neurological diagnostic technologies, is thrilled to announce the awarding of a Small Business Technology Transfer (STTR) Phase II NIH NIA/NINDS grant to conduct a comprehensive pre-market field evaluation of its cutting-edge product, neuropacs™, specifically tailored for Parkinsonism diagnosis.
This STTR Phase II project is designed to rigorously assess the clinical performance of neuropacs™ by integrating it into the workflows of board-certified neurologists. The study aims to determine how the inclusion of neuropacs™ impacts diagnostic accuracy across Parkinson’s disease (PD), Multiple System Atrophy with predominant parkinsonism (MSAp), and Progressive Supranuclear Palsy (PSP). This evaluation is crucial for refining the tool’s ability to support neurologists in making precise and timely diagnoses in the clinical setting.
The outcomes of this Phase II study will advance neuropacs’ mission to develop a high-precision clinical decision support tool for Parkinsonism. Furthermore, it will allow us to embed neuropacsTM to the current workflow of neurologists and test it as a clinical tool in action, paving the way for broader clinical adoption and nationwide distribution.
“We are excited to take neuropacs™ to the next level with this Phase II grant. The testing of the diagnostic capabilities of our product in clinical settings represents a vital step toward revolutionizing the way Parkinsonism is diagnosed and managed,” said Martin Handfield, PhD, CEO of neuropacs Corp..
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.